OncoTargets and Therapy (Oct 2021)
Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib
Abstract
Yanjun Shen,1,* Huige Wang,2,* Jianying Wei,1 Wendong Li1 1Department of Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People’s Republic of China; 2Department of Gynecology, Wangjing Hospital of Chinese Academy of Chinese Medical, Beijing, 100102, People’s Republic of China*These authors contributed equally to this workCorrespondence: Wendong LiDepartment of Oncology, Beijing Ditan Hospital, Capital Medical University, 8 Jingshun East Street, Chaoyang District, Beijing, 100015, People’s Republic of ChinaTel +86-10-84322470Email [email protected]: This cohort study aimed to investigate the influence of fibrinogen on progression-free survival and overall survival in unresectable HCC cases treated by PD-1 and lenvatinib.Methods: A total of 57 unresectable HCC cases who received lenvatinib and PD-1, such as toripalimab, camrelizumab, or sintilimab, in Beijing Ditan Hospital Affiliated to Capital Medical University were enrolled in this study.Results: Vascular invasion, high FIB (> 2.83g/L), and metastasis were highly correlated with low PFS. There was a significant correlation between a raised risk of death and metastasis and increased FIB (> 2.83g/L).Conclusion: FIB is associated with outcomes of unresectable HCC cases treated by PD-1 and lenvatinib.Keywords: FIB, lenvatinib, PD-1, prediction, hepatocellular carcinoma
